276 related articles for article (PubMed ID: 29784745)
1. Updates to the Management of Kidney Cancer.
Jonasch E
J Natl Compr Canc Netw; 2018 May; 16(5S):639-641. PubMed ID: 29784745
[TBL] [Abstract][Full Text] [Related]
2. Pathologic response and surgical outcomes in patients undergoing nephrectomy following receipt of immune checkpoint inhibitors for renal cell carcinoma.
Singla N; Elias R; Ghandour RA; Freifeld Y; Bowman IA; Rapoport L; Enikeev M; Lohrey J; Woldu SL; Gahan JC; Bagrodia A; Brugarolas J; Hammers HJ; Margulis V
Urol Oncol; 2019 Dec; 37(12):924-931. PubMed ID: 31522865
[TBL] [Abstract][Full Text] [Related]
3. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
Gurram S; Al Harthy M; Ball MW
Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer.
Grothey A; Venook AP
J Natl Compr Canc Netw; 2018 May; 16(5S):611-615. PubMed ID: 29784738
[TBL] [Abstract][Full Text] [Related]
5. [Nivolumab combined with ipilimumab versus sunitinib monotherapy-SUNNIFORECAST AN 41/16 of the AUO : A phase 2, randomized, open-label study in subjects with previously untreated and advanced (unresectable or metastatic) non-clear cell renal cell carcinoma].
Rexer H; Steiner T; Bergmann L
Urologe A; 2017 Jun; 56(6):802-803. PubMed ID: 28536740
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma.
Wu B; Zhang Q; Sun J
J Immunother Cancer; 2018 Nov; 6(1):124. PubMed ID: 30458884
[TBL] [Abstract][Full Text] [Related]
7. A Cost-Effectiveness Analysis of Nivolumab and Ipilimumab Versus Sunitinib in First-Line Intermediate- to Poor-Risk Advanced Renal Cell Carcinoma.
Reinhorn D; Sarfaty M; Leshno M; Moore A; Neiman V; Rosenbaum E; Goldstein DA
Oncologist; 2019 Mar; 24(3):366-371. PubMed ID: 30710066
[TBL] [Abstract][Full Text] [Related]
8. First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.
Wallis CJD; Klaassen Z; Bhindi B; Ye XY; Chandrasekar T; Farrell AM; Goldberg H; Boorjian SA; Leibovich B; Kulkarni GS; Shah PS; Bjarnason GA; Heng DYC; Satkunasivam R; Finelli A
Eur Urol; 2018 Sep; 74(3):309-321. PubMed ID: 29656851
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
Tomita Y; Kondo T; Kimura G; Inoue T; Wakumoto Y; Yao M; Sugiyama T; Oya M; Fujii Y; Obara W; Motzer RJ; Uemura H
Jpn J Clin Oncol; 2020 Jan; 50(1):12-19. PubMed ID: 31633185
[TBL] [Abstract][Full Text] [Related]
10. Kidney cancer in 2017: Challenging and refining treatment paradigms.
Ball MW; Srinivasan R
Nat Rev Urol; 2018 Feb; 15(2):77-78. PubMed ID: 29335524
[No Abstract] [Full Text] [Related]
11. Prognostic Significance of the Controlling Nutritional Status (CONUT) Score in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab after Failure of Prior Tyrosine Kinase Inhibitors.
Takemura K; Yuasa T; Fujiwara R; Ito M; Suzuki H; Yonese J; Koga F
J Urol; 2020 Dec; 204(6):1166-1172. PubMed ID: 32567459
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.
Ornstein MC; Wood LS; Hobbs BP; Allman KD; Martin A; Bevan M; Gilligan TD; Garcia JA; Rini BI
J Immunother Cancer; 2019 May; 7(1):127. PubMed ID: 31097024
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
Gharib KE
Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
[No Abstract] [Full Text] [Related]
14. Metastatic Renal Medullary Carcinoma Treated With Immune Checkpoint Inhibitor: Case Report and Literature Review.
Di Stefano RF; Buttigliero C; De Luca E; Reale ML; Pisano C; Leone G; Zichi C; Massa F; Manfredi M; Vignani F; Bollito E; Porpiglia F; Di Maio M; Tucci M
Clin Genitourin Cancer; 2018 Dec; 16(6):e1087-e1090. PubMed ID: 30122516
[No Abstract] [Full Text] [Related]
15. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ; Tannir NM; McDermott DF; Arén Frontera O; Melichar B; Choueiri TK; Plimack ER; Barthélémy P; Porta C; George S; Powles T; Donskov F; Neiman V; Kollmannsberger CK; Salman P; Gurney H; Hawkins R; Ravaud A; Grimm MO; Bracarda S; Barrios CH; Tomita Y; Castellano D; Rini BI; Chen AC; Mekan S; McHenry MB; Wind-Rotolo M; Doan J; Sharma P; Hammers HJ; Escudier B;
N Engl J Med; 2018 Apr; 378(14):1277-1290. PubMed ID: 29562145
[TBL] [Abstract][Full Text] [Related]
16. A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations.
Bex A; Albiges L; Staehler M; Bensalah K; Giles RH; Dabestani S; Hofmann F; Hora M; Kuczyk MA; Lam TB; Marconi L; Merseburger AS; Fernández-Pello S; Tahbaz R; Abu-Ghanem Y; Volpe A; Ljungberg B; Escudier B; Powles T
Eur Urol; 2018 Dec; 74(6):849-851. PubMed ID: 30201510
[No Abstract] [Full Text] [Related]
17. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
Zarrabi K; Wu S
Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for kidney cancer: status quo and the future.
Bedke J; Stühler V; Stenzl A; Brehmer B
Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
[TBL] [Abstract][Full Text] [Related]
20. The landscape of contemporary clinical trials for untreated metastatic clear cell renal cell carcinoma.
Zhang T; Hwang JK; George DJ; Pal SK
Cancer Treat Res Commun; 2020; 24():100183. PubMed ID: 32563923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]